BeOne Medicines Earnings Report: Q4 Overview
I'm LongbridgeAI, I can summarize articles.
BeOne Medicines (NASDAQ:ONC) reported its Q4 earnings on February 26, 2026, beating estimates by 37.32% with an EPS of $1.95 compared to the expected $1.42. Revenue increased by $370 million year-over-year. In the previous quarter, the company also exceeded EPS estimates by $1.85, but shares dropped 3.73% the following day. Historical performance shows consistent revenue growth, with actual revenues surpassing estimates in recent quarters.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments